Halozyme Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $133.8M | $115.9M | $118.4M | $234.2M | $118.7M | $147.7M | $120.2M | $57.9M |
| Accounts Receivable | $426.3M | $288.2M | $233.3M | $231.1M | $91.0M | $97.7M | $59.4M | $30.0M |
| Inventory | $176.5M | $141.9M | $127.6M | $100.1M | $53.9M | $60.7M | $29.4M | $22.6M |
| Total Current Assets | $825.2M | $1.09B | $746.4M | $739.0M | $926.3M | $554.8M | $543.4M | $427.8M |
| Property, Plant & Equipment | $44.4M | $40.9M | $38.1M | $35.1M | $6.8M | $7.3M | $10.9M | $7.5M |
| Goodwill | $580.4M | $416.8M | $416.8M | $409.0M | $0 | — | — | — |
| Intangible Assets (Excl. Goodwill) | $981.5M | $401.8M | $472.9M | $546.7M | $0 | — | — | — |
| Total Assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B | $579.9M | $565.9M | $440.2M |
| Liabilities | ||||||||
| Accounts Payable | $20.9M | $10.2M | $11.8M | $17.7M | $1.5M | $1.9M | $6.4M | $4.1M |
| Total Current Liabilities | $177.1M | $139.1M | $112.5M | $130.8M | $117.1M | $421.4M | $85.6M | $149.4M |
| Long-Term Debt | $2.14B | $1.51B | $1.50B | $1.49B | $787.3M | $0 | $383.0M | $34.9M |
| Total Liabilities | $2.48B | $1.70B | $1.65B | $1.67B | $907.5M | $428.9M | $474.1M | $191.4M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $54.8M | $359.9M | $90.6M | $143.2M | $-58.9M | $-474.6M | $-603.7M | $-531.4M |
| Total Stockholders' Equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M | $151.0M | $91.8M | $248.9M |